elotuzumab (empliciti) Report issue

Biologics mAb Orphan Drug FDA Approved FDA First in Class Priority Review FDA

Active Ingredient History

  • Now
Elotuzumab, sold under the brand name Empliciti, is a humanized IgG1 monoclonal antibody medication used in combination with lenalidomide and dexamethasone, for adults that have received 1 to 3 prior therapies for the treatment of multiple myeloma. It is also indicated for adult patients in combination with pomalidomide and dexamethasone, who have received 2 prior therapies including lenalidomide and a protease inhibitor. Administration of elotuzumab is done intravenously. Each intravenous injection of elotuzumab should be premedicated with dexamethasone, diphenhydramine, ranitidine and acetaminophen. It is being developed by Bristol Myers Squibb and AbbVie.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$1422.6100 - $2488.8600
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

bms-901608 | elotuzumab | empliciti | huluc63 | immunoglobulin g1, anti-(human protein cs1) (human-mouse huluc63 heavy chain), disulfide with human-mouse huluc63 kappa-chain, dimer | immunoglobulin g1, anti-(human slam family member 7 (cd2-like receptor activating cytotoxic cells, cd319 antigen)), humanized mouse monoclonal huluc63 gamma-1 heavy chain (222-214')-disulfide with humanized mouse monoclonal huluc63 kappa light chain (228-228'';231-231'')-bisdisulfide dimer | pdl-063


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue